This inventor holds 3 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Merck Sharp + Dohme Corp., The United States of America as Represented by the Department of Health, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 1995-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2,405 
1 out of 1,217 
1 out of 3,696 
Years Active: 1995-2019
Title: Rachel R Caspi: Innovator in Ocular Inflammation Treatment
Introduction
Rachel R Caspi is a prominent inventor based in Bethesda, MD (US). She has made significant contributions to the field of medical research, particularly in the treatment of inflammatory diseases. With a total of 3 patents, her work focuses on innovative methods to address ocular surface inflammation and autoimmune ocular inflammatory diseases.
Latest Patents
One of her latest patents involves the use of interleukin 24 (IL-24) to treat inflammatory diseases. The methods provided in this patent include selecting a subject with uveitis and/or ocular surface disease. The administration of a therapeutically effective amount of an IL-24 polypeptide or nucleic acid encoding the IL-24 polypeptide is a key aspect of this treatment. In some cases, the administered IL-24 polypeptide suppresses the production of effector cytokines by Th17 cells. Additionally, a pharmaceutical composition is provided that includes an IL-24 polypeptide or nucleic acid encoding the polypeptide, which can be used to treat ocular surface inflammation and/or uveitis.
Another significant patent focuses on the use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease. This patent discloses novel methods and drug products that involve the administration of agents that antagonize one or both of IL-17 and IL-23 activity. These innovative approaches aim to improve treatment outcomes for patients suffering from autoimmune ocular inflammatory conditions.
Career Highlights
Throughout her career, Rachel has worked with esteemed organizations, including the United States of America as represented by the Department of Health and Merck Sharp & Dohme Corp. Her research has been instrumental in advancing the understanding and treatment of ocular inflammatory diseases.
Collaborations
Rachel has collaborated with notable colleagues in her field, including Daniel J Cua and Robert A Kastelein. These partnerships have contributed to the development of her innovative treatments and have furthered research in ocular health.
Conclusion
Rachel R Caspi is a trailblazer in the field of ocular inflammation treatment, with a focus on innovative methods that leverage the power of interleukins. Her contributions through her patents and collaborations continue to impact the medical community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile